Imatinib and Nilotinib: currently used as ABL1-directed inhibitors for CML patients [114,115,116], they were considered to be possible therapeutic agents in HES for their ability to inhibit PDGFR kinase activity. The gene discussed is ABL1; the disease is hypereosinophilic syndrome.